AstraZeneca acquires neuroscience assets from Link Medicine

Friday, July 13, 2012 03:20 PM

AstraZeneca has acquired a portfolio of neuroscience assets from Link Medicine, a privately held biopharmaceutical company based in Massachusetts. Link Medicine has focused its R&D efforts in the field of autophagy, an intracellular process that clears and recycles misfolded proteins, and has been developing potential new treatments for a range of neurodegenerative diseases.

AstraZeneca acquired multiple small molecule assets in clinical and preclinical stages that target the enzyme farnesyltransferase and modulate autophagy. Autophagy is an emerging area of research that can be applied to a range of neurodegenerative diseases, including Parkinson's and Alzheimer's disease, both of which are characterized by a build-up of incorrectly folded, aggregated and ultimately neurotoxic proteins.

The agreement is the third for AstraZeneca's new neuroscience Innovative Medicines Unit, established earlier this year. Under this new model, AstraZeneca is continuing to invest in neuroscience discovery research and early development for small and large molecules by tapping into the best available external science.

AstraZeneca will make specified upfront and milestone payments and will assume all of the program's R&D activities.

Share:          
CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs